These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12939225)

  • 1. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
    Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM
    Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
    Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM
    Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.
    Kooistra T; Verschuren L; de Vries-van der Weij J; Koenig W; Toet K; Princen HM; Kleemann R
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2322-30. PubMed ID: 16873727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
    Monetti M; Canavesi M; Camera M; Parente R; Paoletti R; Tremoli E; Corsini A; Bellosta S
    Pharmacol Res; 2007 May; 55(5):441-9. PubMed ID: 17350858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice.
    Delsing DJ; Post SM; Groenendijk M; Solaas K; van der Boom H; van Duyvenvoorde W; de Wit EC; Bloks VW; Kuipers F; Havekes LM; Princen HM
    J Cardiovasc Pharmacol; 2005 Jan; 45(1):53-60. PubMed ID: 15613980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice.
    Delsing DJ; Jukema JW; van de Wiel MA; Emeis JJ; van der Laarse A; Havekes LM; Princen HM
    J Cardiovasc Pharmacol; 2003 Jul; 42(1):63-70. PubMed ID: 12827028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
    Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
    Calkin AC; Giunti S; Sheehy KJ; Chew C; Boolell V; Rajaram YS; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2008 Sep; 51(9):1731-40. PubMed ID: 18594792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect in insulin-resistant mice.
    Guo H; Lv H; Tang W; Chi J; Liu L; Xu F; Ji Z; Zhai X; Peng F
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):375-82. PubMed ID: 22918601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD.
    Famer D; Wahlund LO; Crisby M
    Biochem Biophys Res Commun; 2010 Nov; 402(2):367-72. PubMed ID: 20946880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet.
    Famer D; Crisby M
    Neurosci Lett; 2007 May; 419(1):68-73. PubMed ID: 17433542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
    Wang JA; Chen WA; Wang Y; Zhang S; Bi H; Hong B; Luo Y; Daugherty A; Xie X
    Atherosclerosis; 2011 Jul; 217(1):90-6. PubMed ID: 21481872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
    Chen J; Li D; Schaefer RF; Mehta JL
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):446-52. PubMed ID: 15454852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
    Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
    Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
    Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
    Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
    Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.
    Funderburg NT; Jiang Y; Debanne SM; Storer N; Labbato D; Clagett B; Robinson J; Lederman MM; McComsey GA
    Clin Infect Dis; 2014 Feb; 58(4):588-95. PubMed ID: 24253250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo imaging of leukocyte recruitment to the atheroprone femoral artery reveals anti-inflammatory effects of rosuvastatin.
    Osaka M; Hagita S; Yoshida M
    Biomed Res Int; 2013; 2013():962369. PubMed ID: 23509822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.